Dose ranges reflect commonly studied amounts in published research models. This is not medical advice. For research use only. Not for human consumption.
Protocol Comparison
Metabolic
Research dose range
Standard research range
1 - 1.5 mg
The approved range — sits across both FDA-cleared formulations, not an estimate built from scratch.
Research focus
Visceral fat reduction / GH-axis stimulation
Observed window
26 weeks
Administration
Once daily
Primary pathway
GHRH receptor, Pituitary somatotroph, IGF-1
Dosing anchored to FDA-approved formulations and the original Phase III trial dose. Mechanism reference: Dhillon S, BioDrugs, 2011. For research use only.
PROTOCOL BENEFITS
◆
Binds the GHRH receptor with high affinity, triggering the pituitary's own natural, pulsatile growth hormone release.
◆
electively targets visceral fat over subcutaneous fat, driven by the higher density of beta-adrenergic receptors in visceral tissue.
◆
Backed by a real Phase III trial — 412 patients, 26 weeks, double-blind and placebo-controlled — the strongest human evidence base in this catalog.
SCIENCE
Tesamorelin is a stabilized analog of the full 44-amino-acid growth hormone-releasing hormone. The stabilization — a trans-3-hexenoic acid group on the N-terminus — protects it from rapid breakdown, giving it enough staying power to reliably trigger the pituitary's own GH release.
This is the one compound in the catalog with an actual FDA approval behind it — granted in 2010 for visceral fat reduction in HIV-associated lipodystrophy, based on a 412-patient, 26-week randomized trial. That's real regulatory ground most peptides in this space never reach
WHAT TO EXPECT
Tesamorelin clears the bloodstream within minutes, but the growth hormone pulse and IGF-1 rise it triggers last far longer — daily dosing keeps that signal running.
PROTOCOL NOTE
Available in 10mg. For research use only. Full documentation included with every order.
FAQ
Tesamorelin is the only one in this class with full FDA approval and Phase III trial data behind it. CJC-1295 offers a longer half-life for less frequent dosing, but doesn't carry the same trial evidence.
The compound itself is short-lived, but it triggers a growth hormone pulse and IGF-1 rise that last far longer. Daily dosing keeps that downstream signal consistent.
